Stay updated on Nivolumab Safety in Chinese Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Safety in Chinese Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Safety in Chinese Solid Tumors Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study record related to the safety and effectiveness of nivolumab in treating advanced or recurrent solid tumors in Chinese subjects.
    Difference
    0.2%
    Check dated 2024-06-06T14:21:41.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include specific eligibility criteria for the study. The new criteria specify that Chinese subjects with advanced or recurrent solid tumors are included, while subjects with brain metastases are excluded unless clinically stable for more than 2 weeks.
    Difference
    11%
    Check dated 2024-05-22T19:54:22.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Summary
    The value 'Go to the classic website' has been updated to 'Site Map' on the webpage, indicating a change in the type of intervention possibly related to medical and healthcare publications and documentation.
    Difference
    2%
    Check dated 2024-05-01T18:12:08.000Z thumbnail image

Stay in the know with updates to Nivolumab Safety in Chinese Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Safety in Chinese Solid Tumors Clinical Trial page.